Reject dogma—embrace nuance in Psychiatry

🔹 Psychoanalysis should not be treated as sacred doctrine. Freud was a clever and influential thinker, but not a prophet.


🔹 Biological psychiatry is equally vulnerable to dogma. Not every symptom signals a disease, and not every distress warrants medication.


🔹 That said, evidence-based pharmacology has its place—especially when medications show clear, replicable benefits in defined clinical conditions.

The future of psychiatry lies in balanced thinking, not blind allegiance—to Freud, to biology, or to any single model of mind.

The Importance of Distinguishing Suicidal Behaviors

This is the subject of a recent discussion I had with a colleague regarding the differences between a suicide attempt and a suicide gesture. Though these terms are sometimes used interchangeably in casual conversation or even in clinical documentation, they carry fundamentally different meanings—both in terms of patient risk and in how we, as clinicians, should respond.

Our conversation emerged from a case involving a patient with borderline personality disorder who presented to the emergency department after ingesting a small quantity of over-the-counter medication. The intent was unclear. Was this a serious attempt to end her life? Or was it a gesture—an act of desperation without the intention to die, but rather to communicate emotional distress?

The question is not academic. Our interpretation of the event determines our risk formulation, our documentation, our treatment planning, and even how we communicate with the patient and their support system. Yet, it is precisely in these gray areas that clinicians often struggle, and where outdated or stigmatizing language can do real harm.

Defining the Terms: Clinical and Functional Differences

suicide attempt refers to an act of self-harm with at least some intent to die. The degree of lethality may vary, but what distinguishes an attempt is that the individual believed the act could result in death and engaged in it with that goal in mind—even if ambivalence was present. The National Institute of Mental Health (NIMH) and the Columbia-Suicide Severity Rating Scale (C-SSRS) define this with some specificity: any potentially self-injurious behavior with non-zerointent to die, regardless of outcome.

In contrast, a suicidal gesture is a behavior that mimics suicidal behavior or appears life-threatening but is typically not intended to be fatal. The function is often communicative or affect-regulating rather than aimed at death. Classic examples include superficial wrist-cutting, ingesting a sub-lethal dose of medication, or tying a noose but not tightening it. These acts often occur in interpersonal contexts and can be seen as efforts to signal pain, elicit help, or assert control in the face of perceived abandonment.

Why the Distinction Matters

It might be tempting to dismiss suicidal gestures as “attention-seeking” or “manipulative,” but this framing is both clinically dangerous and ethically fraught. Individuals who engage in gestures often experience intense psychological suffering, and repeated gestures are a well-established risk factor for future suicide attempts and completed suicide.

From a risk assessment standpoint, gestures should be taken seriously, especially when they become part of a pattern. While the intent to die may not be present in a given gesture, intent can shift quickly, particularly in individuals with mood disorders, personality pathology, or under the influence of substances.

From a treatment perspective, understanding the function of the behavior—whether it is to relieve affective tension, to communicate distress, or to punish oneself—is crucial to tailoring interventions. For instance, dialectical behavior therapy (DBT) explicitly targets self-harm and suicidal gestures as part of its hierarchy of treatment priorities, recognizing the urgency and potential danger of these behaviors even when lethality is low.

Conclusion: Clarify, Don’t Categorize

Ultimately, the conversation with my colleague reminded me that the real clinical challenge is not to label a behavior as a suicide attempt or a gesture, but to understand its meaning in the life of the patient. Both require empathy, structure, and a willingness to engage with complexity. Whether a patient wants to die or wants their suffering to be seen and acknowledged, both deserve serious clinical attention.

By sharpening our definitions and approaching these behaviors with nuance, we can better serve patients in crisis and avoid the pitfalls of assumptions—especially in emotionally charged clinical environments like emergency rooms, inpatient units, or high-acuity outpatient settings.

Managing Mild to Severe Depression: A Guide to Treatment Approaches

It is crucial to recognize that none of the available medications or neuromodulation procedures, including electroconvulsive therapy (ECT) and psychedelics, are disease-modifying. This means that while these treatments can alleviate symptoms, they do not address the underlying causes of depression. Think of them like acetaminophen for a fever—it may temporarily reduce the fever, but without treating the underlying infection, the fever will return.

Neuromodulation refers to techniques that alter brain activity through electrical or magnetic stimulation. Examples include ECT, transcranial magnetic stimulation (TMS), and vagus nerve stimulation (VNS), all of which have been explored as treatments for severe depression.

Optimizing Depression Treatment for Different Severity Levels

Given this understanding, how can we best utilize these treatments to support patients during difficult times? The key is to acknowledge that medications and neuromodulation primarily serve as symptom management tools, most effectively used in the short term for severe cases.

Mild to Moderate Depression: Prioritizing Non-Medication Approaches

For individuals experiencing mild to moderate depression, medication should not be the first line of treFor individuals experiencing mild to moderate depression, medication should not be the first line of treatment. Many people can directly link their depressive symptoms to stressful life events. In such cases, the best initial approach includes:

  • Cognitive Behavioral Therapy (CBT) – Evidence-based therapy that helps reframe negative thinking patterns. Research has shown that CBT is as effective as antidepressants for mild to moderate depression, with relapse rates significantly reduced in those who complete therapy.
  • Lifestyle Modifications – Regular exercise and a healthy diet have strong evidence supporting their role in reducing depressive symptoms. A study published in JAMA Psychiatry found that individuals engaging in at least 150 minutes of moderate exercise per week had a 25% lower risk of developing depression.

For some, these interventions alone may be sufficient to overcome depression and maintain long-term well-being. If additional support is needed, natural supplements with reasonable evidence, such as St. John’s Wort and S-Adenosylmethionine (SAMe), may be considered for mild to moderate depression. However, these supplements are not without risks—St. John’s Wort can interact with many medications, including antidepressants and birth control pills, potentially reducing their effectiveness. SAMe may cause gastrointestinal discomfort or manic symptoms in individuals with bipolar disorder.

Severe Depression: When Medication and Neuromodulation Play a Role

For individuals with severe depression, particularly those at risk for self-harm or suicide, the risks and benefits of medication should be carefully weighed. Antidepressants and neuromodulation therapies have demonstrated the most significant impact in these cases. When selecting a medication, I prioritize those with a lower risk of concerning side effects, particularly sexual dysfunction. My initial choices often include:

  • Bupropion – A dopamine-norepinephrine reuptake inhibitor with a favorable side effect profile.
  • Vortioxetine – Known for its cognitive benefits and relatively low sexual side effects.
  • Mirtazapine – Can be beneficial for those with sleep disturbances or appetite loss.
  • Vilazodone – A serotonin modulator with a lower incidence of sexual dysfunction compared to SSRIs.

It is essential for patients starting antidepressants to be closely monitored, especially in the early weeks of treatment, to assess for side effects and response. Regular follow-ups with a healthcare provider can help adjust dosages or explore alternative treatments if needed.

Treatment Duration and Discontinuation Considerations

For those starting medication, I generally recommend continuing treatment for 6 to 12 months, followed by an assessment to determine whether tapering off is feasible. This process involves shared decision-making, considering:

  • Symptom severity and stability
  • Level of daily functioning
  • Patient’s goals and preferences

The goal is to ensure that the patient has developed effective coping strategies, engaged in therapy, and adopted a healthy lifestyle before considering medication discontinuation. If stopping medication is not advisable, we work to identify the lowest effective dose for long-term maintenance.

Final Thoughts

Depression treatment should be personalized and dynamic, evolving with the patient’s needs. By recognizing that medications and neuromodulation are tools for symptom management rather than cures, we can ensure they are used effectively—providing relief during crises while prioritizing long-term strategies for resilience and recovery.

Can Low-Dose LSD Treat ADHD? A New Study Weighs In

ADHD (Attention-Deficit/Hyperactivity Disorder) affects millions of adults worldwide, with stimulants like methylphenidate and amphetamine being the most effective treatments. But could psychedelics like LSD offer an alternative? A new randomized clinical trial aimed to find out.

👉 Study Overview:

  • Design: Multicenter, double-blind, placebo-controlled trial (N = 53)
  • Participants: Mean age 37 years, 42% female
  • Intervention: Low-dose LSD (20 μg) or placebo twice weekly for 6 weeks (12 doses total)
  • Primary Outcome: Change in ADHD symptoms using the Adult ADHD Investigator Symptom Rating Scale (AISRS)

💡 Key Findings:

  • Both groups showed significant improvement in ADHD symptoms:
    • LSD group: −7.1 points (95% CI, −10.1 to −4.0)
    • Placebo group: −8.9 points (95% CI, −12.0 to −5.8)
  • ✅ LSD was safe and well tolerated
  • ❌ No significant difference between LSD and placebo in symptom reduction

🧠 What This Means:
While low-dose LSD was safe, it didn’t outperform placebo in treating ADHD symptoms. This challenges anecdotal claims about psychedelics for ADHD and reinforces the need for rigorous placebo-controlled trials in psychedelic research.

📈 Future research may explore higher doses or alternative mechanisms—but for now, stimulants remain the gold standard for ADHD treatment.

🔗 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2831639

The Dangers of Overpathologizing Behavioral Issues

Psychiatrists could do the profession—and their patients—a great service by resisting the urge to medicalize every behavioral problem, impulsive act, or mood fluctuation as a direct manifestation of psychiatric illness. While genuine psychiatric disorders exist and require careful diagnosis and treatment, many of the struggles patients face are deeply rooted in the complexities of life itself—financial stress, relationship conflicts, loss, trauma, and systemic issues that no DSM diagnosis can fully capture.

When Life Struggles Are Mistaken for Mental Illness

Certain behaviors and emotional responses are frequently overpathologized. For example:

  • A teenager acting out in school following their parents’ divorce may be labeled with oppositional defiant disorder, when their reaction is a predictable response to emotional distress.
  • A grieving spouse who experiences sadness, tearfulness, and withdrawal beyond a few weeks might be diagnosed with major depressive disorder, despite bereavement being a normal and deeply personal process.
  • A person engaging in impulsive spending or risky behaviors after a significant life change might be quickly categorized as having bipolar disorder, when in reality, they are struggling to cope with a sudden transition.

While these behaviors may be distressing, they do not always indicate the presence of a psychiatric disease requiring medication. Instead, they may reflect normal reactions to adversity that should be addressed through support, coping strategies, and time.

The Risks of Overpathologizing Human Experience

The trend of pathologizing problems of living carries significant consequences. Studies have shown that psychiatric overdiagnosis leads to unnecessary medication use, stigma, and a shift in focus away from addressing social determinants of health. For instance, research suggests that antidepressants are prescribed to 1 in 4 U.S. adults, often for mild or situational distress rather than true clinical depression. Moreover, children—particularly boys—are diagnosed with ADHD at disproportionately high rates, sometimes as a response to difficulties in structured classroom settings rather than a true neurodevelopmental disorder.

Overpathologizing also impacts the credibility of psychiatry. If every struggle is framed as a disorder, the public may begin to view psychiatric diagnoses with skepticism, undermining trust in the profession and the legitimacy of serious mental illnesses.

A Case That Stuck With Me

I once treated a young man who had been brought to the hospital by his family after he quit his job, broke up with his girlfriend, and started making impulsive purchases. His parents were convinced he had bipolar disorder, having read online that sudden life changes and spending sprees were signs of mania. However, after spending time with him, it became clear that his actions were rooted in profound dissatisfaction with his life, not a mood disorder. He was struggling with feelings of stagnation, a lack of purpose, and a desire to redefine himself—not symptoms of an illness, but a human experience.

Despite my clinical assessment, his family was frustrated. They wanted a diagnosis, a label, a treatment plan—something concrete. It was difficult for them to accept that not every distressing experience fits neatly into a medical framework.

How Can Psychiatry Do Better?

Psychiatrists and mental health professionals must be intentional in distinguishing true mental illness from the expected emotional and behavioral responses to life’s challenges. Some ways to do this include:

  • A thorough biopsychosocial assessment that considers the role of environmental, cultural, and situational factors in a patient’s presentation.
  • The judicious use of psychiatric diagnoses, ensuring that labels are assigned only when they accurately reflect a disorder rather than a reaction to stress.
  • Education for patients and families about the natural spectrum of human emotions, helping them understand that distress does not always equate to disease.
  • Advocating for systemic solutions, such as better social support networks, financial resources, and access to therapy, so that emotional struggles are not automatically funneled into the medical system.

Addressing the Counterarguments

Some might argue that withholding a diagnosis could prevent patients from accessing the care they need. While it’s true that a psychiatric label can sometimes be a gateway to services and support, misdiagnosis can be just as harmful. Providing the wrong diagnosis can lead to unnecessary medication, reinforce a sense of pathology where none exists, and obscure the real sources of distress. The challenge for psychiatrists is to walk this fine line carefully—validating suffering without automatically medicalizing it.

Conclusion: A Call for Thoughtful Psychiatry

As psychiatrists, our role is not simply to diagnose and medicate, but to thoughtfully assess and guide. True psychiatric illness must be identified and treated appropriately, but we must also be cautious not to medicalize the normal, albeit painful, struggles of life. The goal should always be to help patients find real, meaningful solutions—whether that means therapy, life changes, or, in some cases, just the reassurance that what they are feeling is part of the human experience.

🧪 Exciting Breakthrough in Cannabis Use Disorder Treatment!

A recent Phase 2b clinical trial has shown that PP-01, an investigational therapy by PleoPharma, significantly reduces cannabis withdrawal symptoms in individuals with Cannabis Use Disorder (CUD). The study demonstrated a clear dose-response relationship, with the highest dose yielding clinically meaningful results (p=0.02). Importantly, PP-01 was well-tolerated with no safety concerns.

Recognizing the urgent need for effective treatments, the FDA has granted Fast Track designation to PP-01, expediting its development and review process. This brings hope to the approximately 19.2 million Americans affected by CUD, as there are currently no FDA-approved medications for cannabis withdrawal.

PP-01 works by targeting suppressed CB1 receptors and neurotransmitter dysregulation in the brain’s reward pathway, offering a novel approach to mitigating withdrawal symptoms. As it enters Phase 3 trials, PP-01 holds promise as a first-in-class treatment for those seeking to overcome cannabis dependence.

🚨 Health Care is Under Attack

Our patients are under attack. Our oath to do no harm is under attack. Health care is under attack.

Last week, the U.S. House of Representatives passed a budget resolution that could slash $880 billion from Medicaid—a devastating blow that would strip 15.9 million people of health coverage. That’s 1 in 5 of your friends, neighbors, and patients.

📉 Who will suffer most?
🔹 Children
🔹 The elderly
🔹 People with disabilities
🔹 Those living in poverty

These are the people we serve every day

We cannot stand by as essential care is ripped away from the most vulnerable. This is not a red or blue issue —this is a people issue.

🩺 If you’re a healthcare professional, patient, or advocate, now is the time to speak up. Join us in the fight to protect Medicaid and ensure no one is left behind.

🧠 Microplastics in the Brain: A Rising Concern for Mental Health? 🧠

New research reveals that microplastics and nanoplastics (MNPs) have been accumulating in the human brain at increasing levels from 2016 to 2024—and in higher concentrations than in other organs. 😳

What does this mean for mental health? While the psychiatric implications are still being explored, potential concerns include:
🔬 Neuroinflammation – A known factor in mood and cognitive disorders.
🧩 Blood-brain barrier disruption – Could impact neurotransmission.
⚡ Oxidative stress & toxicity – Possible links to neurodegenerative and psychiatric conditions.

🚨 Big picture: We need more research, but growing evidence suggests environmental factors like MNP exposure could play a role in brain health and psychiatric disorders.

The Pill Won’t Solve It All 💊🚫

When every problem you face has been treated exclusively by a pill, you start to believe that the answer to all your struggles lies in finding the right one. 🤔💡

With this mindset, you will never be well. 🧠❌

It’s no different than someone searching for the perfect car 🚗 or the dream home 🏡 to fix their life. Sure, it might bring temporary relief, but in the end, it steals your power, leaving your happiness dependent on external factors you can’t control. 🎭🔗

True healing starts when you reclaim your own agency. 💪🔥

Semaglutide (#Ozempic / #Wegovy) Reduced Alcohol & Nicotine Use in a First-of-Its-Kind RCT

📉 In a randomized trial with 48 patients diagnosed with #AlcoholUseDisorder, semaglutide significantly lowered alcohol intake in a controlled lab setting.

🚬 Interestingly, nicotine consumption also decreased.

💉 Low doses (0.25-1 mg/week) were used over 9 weeks—much lower than standard obesity or diabetes dosing.

🔬 More research is needed, but this adds to growing evidence that GLP-1 agonists may impact addictive behaviors.

Link to article: https://pubmed.ncbi.nlm.nih.gov/39937469/

Powered by WordPress.com.

Up ↑